<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03722927</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00045562</org_study_id>
    <nct_id>NCT03722927</nct_id>
  </id_info>
  <brief_title>The Use Of Liposomal Bupivacaine For Pain Control</brief_title>
  <official_title>The Use of Liposomal Bupivacaine for Pain Control Following Mastectomy and Breast Reconstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine how well the local anesthetic, liposomal
      bupivacaine, controls postoperative pain after mastectomy and breast reconstruction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible subjects will be identified prior to surgery. On the day of surgery, each patient
      will be randomized to be in either Local infiltration of bupivacaine OR liposomal
      bupivacaine. Study will be double blinded to patients and Investigators. Patients assigned to
      the local infiltration with bupivacaine group will receive a total 60 ml of 0.25% bupivacaine
      with 30 ml delivered to each breast. Patients assigned to the local infiltration of liposomal
      bupivacaine will receive a total of 20 ml liposomal bupivacaine (266 mg) with 10 ml of 0.25%
      bupivacaine and 30 ml of 0.9% sodium chloride. These injections will occur at the end of the
      mastectomy and prior to the insertion of the tissue expander implant. After this
      intraoperative injection, patients will not receive any more doses of local anesthetics.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 14, 2018</start_date>
  <completion_date type="Actual">January 29, 2020</completion_date>
  <primary_completion_date type="Actual">January 29, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Women of all races and ethnicity who meet the above-described eligibility criteria are eligible to participate in this study. Approximately 5% of study participants to be Hispanic/Latino (N=5), 10% Black or African American (N=10), 1% American Indian/Alaska Native (N=1), and 5% Asian (N=5).</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Visual Analog Scores</measure>
    <time_frame>48 hours</time_frame>
    <description>This will be measured every 12 hours for the first 48 hours postoperatively by the level of breast pain associated with arm movements while eating on a scale of 0-10 with higher scores denoting worse outcomes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve Visual Analog Scores (Submuscular Augmentation Mammoplasty)</measure>
    <time_frame>48 hours</time_frame>
    <description>This will be measured during first 48 hours postoperatively on a scale of 0-10 with higher scores denoting worse outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morphine Equivalents</measure>
    <time_frame>1 Month</time_frame>
    <description>This will be measured by the number of doses within the first month postoperatively and recorded on pain medication daily diary kept by subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay for hospitalization</measure>
    <time_frame>up to 47 Hours</time_frame>
    <description>The length of stay for hospitalization after mastectomy and breast reconstruction will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission rates to the hospital</measure>
    <time_frame>Month 2</time_frame>
    <description>Readmission rates to the hospital within 2 months after mastectomy and breast reconstruction will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of postoperative opioid related adverse effects</measure>
    <time_frame>Postoperatively, 1 week</time_frame>
    <description>Frequency of postoperative opioid related adverse effects within the first week of surgery will be recorded. This includes nausea, vomiting, pruritus, allergy, respiratory depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain intensity with movement</measure>
    <time_frame>Up to 2 months</time_frame>
    <description>This will be measured by using the Pain Assessment Questionnaire. Total scores are 0-50 with higher scores denoting worse outcomes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Pain, Breast</condition>
  <arm_group>
    <arm_group_label>Bupivacaine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to the Bupivacaine Group and receive a bilateral mastectomy with immediate implant based breast reconstruction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liposomal Bupivacaine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to the Liposomal Bupivacaine Group and receive a bilateral mastectomy with immediate implant based breast reconstruction</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>While in the operating room,if subject is randomized to bupivacaine, it will be injected into the surgical site. After surgery, oral and IV pain medications will be available to control pain. During the hospital stay, subject will rate pain on pain scales and monitor how much pain medications needed. Once discharged, PI/staff will provide a pain diary to record pain medication use and pain rating (0-10). Subjects will follow up with clinic at regularly scheduled appointment times at 1 week, 3 weeks and 5 weeks postoperatively. At those appointments, PI/staff will have subjects bring pain medication diary and fill out a pain assessment and a disability assessment related to recent surgery.</description>
    <arm_group_label>Bupivacaine Group</arm_group_label>
    <other_name>Marcaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Bupivacaine</intervention_name>
    <description>While in the operating room,if subject is randomized to Liposomal Bupivacaine, it will be injected into the surgical site. After surgery, oral and IV pain medications will be available to control pain. During the hospital stay, subject will rate pain on pain scales and monitor how much pain medications needed. Once discharged, PI/staff will provide a pain diary to record pain medication use and pain rating (0-10). Subjects will follow up with clinic at regularly scheduled appointment times at 1 week, 3 weeks and 5 weeks postoperatively. At those appointments, PI/staff will have subjects bring pain medication diary and fill out a pain assessment and a disability assessment related to recent surgery.</description>
    <arm_group_label>Liposomal Bupivacaine Group</arm_group_label>
    <other_name>Exparel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients who receive a bilateral mastectomy with immediate sub-pectoral implant
             based breast reconstruction

          -  Age â‰¥ 18 years

          -  Ability to understand and the willingness to sign an (Institutional Review Board)
             IRB-approved informed consent document.

          -  Patients who receive tissue expander placement or direct permanent implant placement
             will be included in the study.

        Exclusion Criteria:

          -  Patients who receive an autologous tissue reconstruction.

          -  Patients who receive a unilateral reconstruction.

          -  Patients who are expected to undergo axillary lymph node dissection

          -  Patients who have undergone breast irradiation

          -  Patients who abuse narcotics or have chronic pain (using greater than 40 mg
             equivalents of oxycodone per day)

          -  Patients who are wards of the state

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to bupivacaine or liposomal bupivacaine.

          -  Pregnant women are excluded from this study because pregnancy precluded immediate
             breast reconstruction in our patient population.

          -  Patients who weigh less than 50 kg, as there can be dose related toxicities of the
             bupivacaine dosing used n this study.

          -  Patients with moderate-severe hepatic or renal impairment because of the increased
             risk of toxicity.

          -  Patients receiving bilateral mastectomy with immediate pre-pectoral implant based
             reconstruction
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher M Runyan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lovecchio F, Jordan SW, Lim S, Fine NA, Kim JY. Risk Factors for Complications Differ Between Stages of Tissue-Expander Breast Reconstruction. Ann Plast Surg. 2015 Sep;75(3):275-80. doi: 10.1097/SAP.0000000000000109.</citation>
    <PMID>24691330</PMID>
  </reference>
  <reference>
    <citation>Butz DR, Shenaq DS, Rundell VL, Kepler B, Liederbach E, Thiel J, Pesce C, Murphy GS, Sisco M, Howard MA. Postoperative Pain and Length of Stay Lowered by Use of Exparel in Immediate, Implant-Based Breast Reconstruction. Plast Reconstr Surg Glob Open. 2015 Jun 5;3(5):e391. doi: 10.1097/GOX.0000000000000355. eCollection 2015 May.</citation>
    <PMID>26090281</PMID>
  </reference>
  <reference>
    <citation>Ng SK, Hare RM, Kuang RJ, Smith KM, Brown BJ, Hunter-Smith DJ. Breast Reconstruction Post Mastectomy: Patient Satisfaction and Decision Making. Ann Plast Surg. 2016 Jun;76(6):640-4. doi: 10.1097/SAP.0000000000000242.</citation>
    <PMID>25003439</PMID>
  </reference>
  <reference>
    <citation>Shekhawat L, Busheri L, Dixit S, Patel C, Dhar U, Koppiker C. Patient-Reported Outcomes Following Breast Reconstruction Surgery and Therapeutic Mammoplasty: Prospective Evaluation 1 Year Post-Surgery with BREAST-Q Questionnaire. Indian J Surg Oncol. 2015 Dec;6(4):356-62. doi: 10.1007/s13193-015-0432-x. Epub 2015 Jul 23.</citation>
    <PMID>27065661</PMID>
  </reference>
  <reference>
    <citation>Wallace MS, Wallace AM, Lee J, Dobke MK. Pain after breast surgery: a survey of 282 women. Pain. 1996 Aug;66(2-3):195-205.</citation>
    <PMID>8880841</PMID>
  </reference>
  <reference>
    <citation>Morrison JE Jr, Jacobs VR. Reduction or elimination of postoperative pain medication after mastectomy through use of a temporarily placed local anesthetic pump vs. control group. Zentralbl Gynakol. 2003 Jan;125(1):17-22.</citation>
    <PMID>12877104</PMID>
  </reference>
  <reference>
    <citation>Lee MJ, Daniels SL, Wild JRL, Wilson TR; SYSuRG RAGeS Group. Readmissions after general surgery: a prospective multicenter audit. J Surg Res. 2017 Mar;209:53-59. doi: 10.1016/j.jss.2016.09.020. Epub 2016 Sep 19.</citation>
    <PMID>28032571</PMID>
  </reference>
  <reference>
    <citation>Bonnet F, Marret E. Influence of anaesthetic and analgesic techniques on outcome after surgery. Br J Anaesth. 2005 Jul;95(1):52-8. Epub 2004 Dec 3. Review.</citation>
    <PMID>15579487</PMID>
  </reference>
  <reference>
    <citation>Strang P. Cancer pain--a provoker of emotional, social and existential distress. Acta Oncol. 1998;37(7-8):641-4. Review.</citation>
    <PMID>10050980</PMID>
  </reference>
  <reference>
    <citation>ZieliÅ„ski T, Lorenc-PodgÃ³rska K, Antoszewski B. Why women who have mastectomy decide not to have breast reconstruction? Pol Przegl Chir. 2015 Feb 3;86(10):451-5. doi: 10.2478/pjs-2014-0081.</citation>
    <PMID>25720103</PMID>
  </reference>
  <reference>
    <citation>American Society of Plastic Surgeons. (2015). Plastic surgery statistics report. Retrived from https://d2wirczt3b6wjm.cloudfront.net/News/Statistics/2015/plastic-surgery-statistics-full-report-2015.pdf</citation>
  </reference>
  <reference>
    <citation>Gassman AA, Yoon AP, Festekjian J, Da Lio AL, Tseng CY, Crisera C. Comparison of immediate postoperative pain in implant-based breast reconstructions. J Plast Reconstr Aesthet Surg. 2016 May;69(5):604-16. doi: 10.1016/j.bjps.2015.12.009. Epub 2016 Jan 7.</citation>
    <PMID>26947947</PMID>
  </reference>
  <reference>
    <citation>Ilfeld BM, Viscusi ER, Hadzic A, Minkowitz HS, Morren MD, Lookabaugh J, Joshi GP. Safety and Side Effect Profile of Liposome Bupivacaine (Exparel) in Peripheral Nerve Blocks. Reg Anesth Pain Med. 2015 Sep-Oct;40(5):572-82. doi: 10.1097/AAP.0000000000000283.</citation>
    <PMID>26204387</PMID>
  </reference>
  <reference>
    <citation>Viscusi ER, Sinatra R, Onel E, Ramamoorthy SL. The safety of liposome bupivacaine, a novel local analgesic formulation. Clin J Pain. 2014 Feb;30(2):102-10. doi: 10.1097/AJP.0b013e318288e1f6.</citation>
    <PMID>23446090</PMID>
  </reference>
  <reference>
    <citation>Khalil KG, Boutrous ML, Irani AD, Miller CC 3rd, Pawelek TR, Estrera AL, Safi HJ. Operative Intercostal Nerve Blocks With Long-Acting Bupivacaine Liposome for Pain Control After Thoracotomy. Ann Thorac Surg. 2015 Dec;100(6):2013-8. doi: 10.1016/j.athoracsur.2015.08.017. Epub 2015 Oct 24.</citation>
    <PMID>26507422</PMID>
  </reference>
  <reference>
    <citation>Fayezizadeh M, Majumder A, Neupane R, Elliott HL, Novitsky YW. Efficacy of transversus abdominis plane block with liposomal bupivacaine during open abdominal wall reconstruction. Am J Surg. 2016 Sep;212(3):399-405. doi: 10.1016/j.amjsurg.2015.12.026. Epub 2016 Apr 12.</citation>
    <PMID>27156796</PMID>
  </reference>
  <reference>
    <citation>Rawlani V, Kryger ZB, Lu L, Fine NA. A local anesthetic pump reduces postoperative pain and narcotic and antiemetic use in breast reconstruction surgery: a randomized controlled trial. Plast Reconstr Surg. 2008 Jul;122(1):39-52. doi: 10.1097/PRS.0b013e3181774349.</citation>
    <PMID>18594373</PMID>
  </reference>
  <reference>
    <citation>Nadeau MH, Saraswat A, Vasko A, Elliott JO, Vasko SD. Bupivacaine Versus Liposomal Bupivacaine for Postoperative Pain Control after Augmentation Mammaplasty: A Prospective, Randomized, Double-Blind Trial. Aesthet Surg J. 2016 Feb;36(2):NP47-52. doi: 10.1093/asj/sjv149. Epub 2015 Dec 23.</citation>
    <PMID>26704270</PMID>
  </reference>
  <reference>
    <citation>Smoot JD, Bergese SD, Onel E, Williams HT, Hedden W. The efficacy and safety of DepoFoam bupivacaine in patients undergoing bilateral, cosmetic, submuscular augmentation mammaplasty: a randomized, double-blind, active-control study. Aesthet Surg J. 2012 Jan;32(1):69-76. doi: 10.1177/1090820X11430831. Epub 2011 Dec 16.</citation>
    <PMID>22179931</PMID>
  </reference>
  <reference>
    <citation>Coopey SB, Specht MC, Warren L, Smith BL, Winograd JM, Fleischmann K. Use of preoperative paravertebral block decreases length of stay in patients undergoing mastectomy plus immediate reconstruction. Ann Surg Oncol. 2013 Apr;20(4):1282-6. doi: 10.1245/s10434-012-2678-7. Epub 2012 Oct 14.</citation>
    <PMID>23064793</PMID>
  </reference>
  <reference>
    <citation>Andersen KG, Christensen KB, Kehlet H, Bidstup PE. The Effect of Pain on Physical Functioning After Breast Cancer Treatment: Development and Validation of an Assessment Tool. Clin J Pain. 2015 Sep;31(9):794-802. doi: 10.1097/AJP.0000000000000156.</citation>
    <PMID>25679946</PMID>
  </reference>
  <reference>
    <citation>Campbell I, Cavanagh S, Creighton J, French R, Banerjee S, Kerr E, Shirley R. To infiltrate or not? Acute effects of local anaesthetic in breast surgery. ANZ J Surg. 2015 May;85(5):353-7. doi: 10.1111/ans.12541. Epub 2014 Apr 22.</citation>
    <PMID>24754798</PMID>
  </reference>
  <reference>
    <citation>Byager N, Hansen MS, Mathiesen O, Dahl JB. The analgesic effect of wound infiltration with local anaesthetics after breast surgery: a qualitative systematic review. Acta Anaesthesiol Scand. 2014 Apr;58(4):402-10. doi: 10.1111/aas.12287. Review.</citation>
    <PMID>24617619</PMID>
  </reference>
  <reference>
    <citation>Zielinski J, Jaworski R, Smietanska I, Irga N, Wujtewicz M, Jaskiewicz J. A randomized, double-blind, placebo-controlled trial of preemptive analgesia with bupivacaine in patients undergoing mastectomy for carcinoma of the breast. Med Sci Monit. 2011 Oct;17(10):CR589-97.</citation>
    <PMID>21959614</PMID>
  </reference>
  <reference>
    <citation>Tam KW, Chen SY, Huang TW, Lin CC, Su CM, Li CL, Ho YS, Wang WY, Wu CH. Effect of wound infiltration with ropivacaine or bupivacaine analgesia in breast cancer surgery: A meta-analysis of randomized controlled trials. Int J Surg. 2015 Oct;22:79-85. doi: 10.1016/j.ijsu.2015.07.715. Epub 2015 Aug 12. Review.</citation>
    <PMID>26277531</PMID>
  </reference>
  <reference>
    <citation>US Food and Drug Administration. FDA Label Approved on 10/28/2011 for Exparel. US Silver Spring, MD: US Food and Drug Administration. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022496s000lbl.pdf</citation>
  </reference>
  <reference>
    <citation>Golf M, Daniels SE, Onel E. A phase 3, randomized, placebo-controlled trial of DepoFoamÂ® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy. Adv Ther. 2011 Sep;28(9):776-88. doi: 10.1007/s12325-011-0052-y. Epub 2011 Aug 12.</citation>
    <PMID>21842428</PMID>
  </reference>
  <reference>
    <citation>Gorfine SR, Onel E, Patou G, Krivokapic ZV. Bupivacaine extended-release liposome injection for prolonged postsurgical analgesia in patients undergoing hemorrhoidectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Dis Colon Rectum. 2011 Dec;54(12):1552-9. doi: 10.1097/DCR.0b013e318232d4c1.</citation>
    <PMID>22067185</PMID>
  </reference>
  <reference>
    <citation>US Food and Drug Administration. Marcaine Bupivcacaine HCl Injection Label. US Silver Spring, MD: US Food and Drug Administration. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/018692s015lbl.pdf</citation>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>October 22, 2018</study_first_submitted>
  <study_first_submitted_qc>October 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2018</study_first_posted>
  <last_update_submitted>January 30, 2020</last_update_submitted>
  <last_update_submitted_qc>January 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bupivacaine</keyword>
  <keyword>Liposomal Bupivacaine</keyword>
  <keyword>Mastectomy</keyword>
  <keyword>Breast Reconstruction</keyword>
  <keyword>Pain Control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mastodynia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 8, 2020</submitted>
    <returned>May 26, 2020</returned>
    <submitted>June 5, 2020</submitted>
    <submission_canceled>June 9, 2020</submission_canceled>
    <submitted>June 10, 2020</submitted>
    <returned>June 30, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

